Human and bovine rotavirus strain antigens for evaluation of immunogenicity in a randomized, double-blind, placebo-controlled trial of a single dose live attenuated tetravalent, bovine-human-reassortant, oral rotavirus vaccine in Indian adults

被引:15
|
作者
Paul, Anu [1 ]
Babji, Sudhir [1 ]
Sowmyanarayanan, T. V. [1 ]
Dhingra, Mandeep Singh [2 ]
Ramani, Sasirekha [1 ]
Kattula, Deepthi [1 ]
Kang, Gagandeep [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Wellcome Trust Res Lab, Vellore 632004, Tamil Nadu, India
[2] Shantha Biotech Ltd, Hyderabad, Andhra Pradesh, India
关键词
Rotavirus vaccines; India; BRV-TV; Safety; Immunogenicity; YOUNG-CHILDREN; SAFETY; INFANTS; DIARRHEA; UK; GASTROENTERITIS; PROTECTION; CANDIDATES; SEROTYPES; EFFICACY;
D O I
10.1016/j.vaccine.2014.03.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A single dose of live attenuated tetravalent (G1-G4) bovine human reassortant rotavirus vaccine (BRV-TV) was administered to healthy Indian adult volunteers, who were assessed for safety and immunogenicity of the vaccine with 3:1 randomization to vaccine or placebo. All 20 adult male volunteers in the study had rotavirus specific serum IgA at baseline. There were no side effects or adverse events reported. Administration of BRV-TV was not associated with fever, diarrhea, or altered liver transaminases. Rotavirus IgA seroconversion post single dose administration was 27%. This study shows that BRV-TV is non-reactogenic, safe and immunogenic in adults. The IgA units estimated for the same sample using human GIP[8] rotavirus strain as the antigen were consistently higher than with the bovine G6P[5] WC3 strain and the human G2P[4] DS-1 strain antigen. The use of different human and bovine rotavirus strains as antigens in a quantitative rotavirus specific serum IgA assay resulted in different estimations of IgA antibody in the same sample. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3094 / 3100
页数:7
相关论文
共 50 条
  • [41] Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants
    Clements-Mann, ML
    Makhene, MK
    Mrukowicz, J
    Wright, PF
    Hoshino, Y
    Midthun, K
    Sperber, E
    Karron, R
    Kapikian, AZ
    VACCINE, 1999, 17 (20-21) : 2715 - 2725
  • [42] The ORVAC trial protocol: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis
    Middleton, Bianca Fleur
    Jones, Mark A.
    Waddington, Claire S.
    Danchin, Margaret
    McCallum, Carly
    Gallagher, Sarah
    Leach, Amanda Jane
    Andrews, Ross
    Kirkwood, Carl
    Cunliffe, Nigel
    Carapetis, Jonathan
    Marsh, Julie A.
    Snelling, Tom
    BMJ OPEN, 2019, 9 (11):
  • [43] Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial
    Malloy, Jaret
    Zhuang, Dongliang
    Kim, Terri
    Inskeep, Phil
    Kim, Dennis
    Taylor, Kristin
    DIABETES OBESITY & METABOLISM, 2018, 20 (08) : 1878 - 1884
  • [44] Safety and Immunogenicity of the ID93+GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Choi, Yu Hwa
    Kang, Young Ae
    Park, Kwang Joo
    Choi, Jae Chol
    Cho, Kwan Goo
    Ko, Da Yeon
    Ahn, Jun Ho
    Lee, Boram
    Ahn, Eunsol
    Woo, Yun Ju
    Jung, Kwangsoo
    Kim, Nan Yul
    Reese, Valerie A. A.
    Larsen, Sasha E. E.
    Baldwin, Susan L. L.
    Reed, Steven G. G.
    Coler, Rhea N. N.
    Lee, Hyejon
    Cho, Sang-Nae
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (06) : 1605 - 1624
  • [45] Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults
    Jin, Zhili
    Wu, Jingxuan
    Wang, Ying
    Huang, Tao
    Zhao, Kexin
    Liu, Jian
    Wang, Haomeng
    Zhu, Tao
    Gou, Jinbo
    Huang, Haitao
    Wu, Xiaofang
    Yin, Hang
    Song, Jian
    Li, Ran
    Zhang, Jianxiong
    Li, Lijun
    Chen, Jingcheng
    Li, Xiao
    Zhang, Meijuan
    Li, Jiangshuo
    Hou, Mengyu
    Song, Yuqin
    Wang, Bingyan
    Gao, Qiannan
    Wu, Le
    Kong, Yanhong
    Dong, Ruihua
    JOURNAL OF INFECTION, 2023, 87 (06) : 556 - 570
  • [46] Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
    Shu, Ya-Jun
    He, Jian-Feng
    Pei, Rong-Juan
    He, Peng
    Huang, Zhu-Hang
    Chen, Shao-Min
    Ou, Zhi-Qiang
    Deng, Jing-Long
    Zeng, Pei-Yu
    Zhou, Jian
    Min, Yuan-Qin
    Deng, Fei
    Peng, Hua
    Zhang, Zheng
    Wang, Bo
    Xu, Zhong-Hui
    Guan, Wu-Xiang
    Hu, Zhong-Yu
    Zhang, Ji-Kai
    CHINESE MEDICAL JOURNAL, 2021, 134 (16) : 1967 - 1976
  • [47] Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
    Shu Ya-Jun
    He Jian-Feng
    Pei Rong-Juan
    He Peng
    Huang Zhu-Hang
    Chen Shao-Min
    Ou Zhi-Qiang
    Deng Jing-Long
    Zeng Pei-Yu
    Zhou Jian
    Min Yuan-Qin
    Deng Fei
    Peng Hua
    Zhang Zheng
    Wang Bo
    Xu Zhong-Hui
    Guan Wu-Xiang
    Hu Zhong-Yu
    Zhang Ji-Kai
    中华医学杂志英文版, 2021, 134 (16) : 1967 - 1976
  • [48] Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Yu Hwa Choi
    Young Ae Kang
    Kwang Joo Park
    Jae Chol Choi
    Kwan Goo Cho
    Da Yeon Ko
    Jun Ho Ahn
    Boram Lee
    Eunsol Ahn
    Yun Ju Woo
    Kwangsoo Jung
    Nan Yul Kim
    Valerie A. Reese
    Sasha E. Larsen
    Susan L. Baldwin
    Steven G. Reed
    Rhea N. Coler
    Hyejon Lee
    Sang-Nae Cho
    Infectious Diseases and Therapy, 2023, 12 : 1605 - 1624
  • [49] Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females
    Li, Rongcheng
    Li, Yanping
    Radley, David
    Liu, Youping
    Huang, Teng
    Sings, Heather L.
    Zhang, Lingling
    Wang, Wei
    Zhong, Xiang
    Saah, Alfred J.
    VACCINE, 2012, 30 (28) : 4284 - 4291
  • [50] Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: A randomized, placebo-controlled, double-blind study
    Burton, J. P.
    Cowley, S.
    Simon, R. R.
    McKinney, J.
    Wescombe, P. A.
    Tagg, J. R.
    FOOD AND CHEMICAL TOXICOLOGY, 2011, 49 (09) : 2356 - 2364